The global biobanking market is anticipated to grow at a considerable CAGR of 6.7% during the forecast period (2021-2027). The market growth is mainly attributed to the rise in cancer patients across the globe leading to an increase in the number of researchers. According to the reports of the World Health Organization, cancer was estimated to be the leading cause of death in 2020 accounting for nearly 10 million deaths across the globe in the same year. Breast cancer was estimated to account for nearly 2.26 million cases and the most common cause of cancer death in 2020 was lung cancer which accounted for around 1.8 million deaths globally. The rise in the number of cancer patients has increased the number of researches to deliver proper treatment. Moreover, collaborations between the private and public institutions have played a vital role in providing growth to the market share. Supportive government initiatives and policies have also contributed to the growth of pharmaceutical biobanks. For instance, in 2018, The Ethics Advisory Committee (EAC) was established to provide advice to the Board on ethical issues that arise during the maintenance, development, and use of the UK Biobank.
Browse the full report description of "Global Biobanking Market Size, Share & Trends Analysis Report by Product Type (Equipment, Consumables, and Services & Software), By Sample Type (Blood Products, Human Tissues, Nucleic Acid, Cell Lines, Biological Fluid, and Human Waste Product), and by Applications (Clinical Research, and Regenerative Medicine) Forecast, 2021-2027" at https://www.omrglobal.com/industry-reports/biobanking-market
Moreover, In February 2019, Danaher Corp. announced that it has reached a definitive agreement with General Electric Co. to buy GE Life Sciences' Biopharma business ("GE Biopharma") for $21.4 billion. In May 2021, Vigene Biosciences Inc., a leading U.S.-based gene therapy contract development and manufacturing organization (CDMO) that specializes in viral vector-based gene delivery technologies have been acquired by Charles River Laboratories International Inc. The purchase price was estimated to be roughly $292.5 million.
In January 2019, MediSapiens, a leading developer and provider of genomic, biomedical, and health data solutions, has formed a partnership with Modul-Bio, a leading provider of biological sample management solutions, Biobank Information Management Systems (BIMS), and collaborative tools for sharing biological sample collections. The two companies have done this collaboration with hoping that this complement one other's biobanking solutions, giving biobanks an all-around capability for managing, exchanging, and commercializing their samples and data. Thus, the rising prevalence of cancer cases, rising demand for the biobanks, and the major player's initiatives such as partnerships, collaborations, and mergers and acquisitions are to drive the market growth during the forecast period.
Market Coverage
o By Product Type
o By Sample Type
o By Application
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Bio-Banking Market Report Segment
By Product Type
By Sample Type
By Application
Global Bio-Banking Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/biobanking-market